Avistone Biotechnology Co., Ltd.
Clinical trials sponsored by Avistone Biotechnology Co., Ltd., explained in plain language.
-
New cancer drug enters first human trials for Tough-to-Treat tumors
Disease control Recruiting nowThis is the first study in humans testing a new drug called ANS03 for people with advanced solid tumors that have specific genetic changes (ROS1 or NTRK). The main goals are to check the drug's safety, how the body processes it, and look for early signs that it might help control…
Phase: PHASE1 • Sponsor: Avistone Biotechnology Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug trial targets Tough-to-Treat lung cancer mutations
Disease control Recruiting nowThis study is testing a new targeted drug called andamertinib, given alone or with standard chemotherapy, for people with advanced non-small cell lung cancer. It is for patients who have a specific, less common type of genetic change (atypical EGFR mutation) and have not yet rece…
Phase: PHASE2 • Sponsor: Avistone Biotechnology Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
First patients receive experimental cancer drug in early safety trial
Disease control Recruiting nowThis is the first study in people to test a new drug called ANS014004 for advanced solid tumors that have spread or cannot be removed by surgery. The main goal is to find a safe dose and understand how the body processes the drug in about 63 adult participants. Researchers will a…
Phase: PHASE1 • Sponsor: Avistone Biotechnology Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC